Published • loading... • Updated
FDA: Mifepristone review won’t be done until March
The agency will compare mifepristone with surgical abortions and review side effects in about 100,000 women before issuing a final report.
- The Justice Department filed a court document Wednesday confirming The FDA expects to complete its safety review of the abortion pill mifepristone in March, responding to a federal judge in Louisiana's order for a progress report.
- Health Secretary Robert F. Kennedy Jr. commissioned the review last year after a conservative think tank alleged higher complication rates from mifepristone, though Researchers labeled those findings 'junk science' never peer-reviewed or published.
- The FDA will measure side effects among roughly 100,000 women, comparing mifepristone's safety to surgical abortions through 10 weeks of gestation in the comprehensive review.
- As a defendant in a Louisiana suit challenging telehealth access, the agency faces pressure from Republicans including Sen. Bill Cassidy, while nominee Heidi Overton sidestepped mifepristone safety questions at her confirmation hearing.
- The review's March completion date falls months after the Nov. 3 midterm elections, when abortion access remains among voters' key concerns, potentially influencing the political landscape around mifepristone access.
Insights by Ground AI
20 Articles
20 Articles
FDA says its review of abortion pill will continue into next year – WTOP News
WASHINGTON (AP) — The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year, a timeline that was quickly condemned by abortion opponents hoping to see the drug’s use curtailed. The FDA gave a court-ordered update on its progress in a legal filing late Wednesday, providing the first substantive information about the controversial reevaluation ordered by Health Secretary Robert …
·Chevy Chase, United States
Read Full Article
FDA says its safety review of abortion pill will continue into next ye
WASHINGTON (AP) — The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year, a timeline that was quickly condemned by abortion opponents hoping to see the
·Baltimore, United States
Read Full Article
Coverage Details
Total News Sources20
Leaning Left12Leaning Right1Center6Last UpdatedBias Distribution63% Left
Bias Distribution
- 63% of the sources lean Left
63% Left
L 63%
C 32%
Factuality
To view factuality data please Upgrade to Premium
